GLP-1 receptor agonists became investable as a structurally transformative metabolic-disease franchise during 2021 to 2026. The pivot started with Wegovy (semaglutide 2.4mg, FDA June 2021) for chronic weight management, accelerated with Zepbound (tirzepatide, FDA November 2023), and broadened through cardiovascular (Wegovy March 2024), obstructive sleep apnea (Zepbound December 2024), chronic kidney disease (semaglutide January 2025), and MASH (semaglutide ESSENCE Phase 3 published 2025) label expansions. Class brand sales project approximately $80 billion in 2026 (IQVIA Outlook for Obesity 2026) and toward $150 billion annually by 2030. The investable question has shifted from 'is the class real' to 'who captures what share' across incumbents, late-stage challengers, peptide CDMOs and device makers, payers and PBMs, and the indications expansion arc.

The second-order story is consolidation, access reset, and pipeline diversification. M&A and licensing deal value 2023 to 2025 exceeded 50 billion dollars: Roche-Carmot 2.7B (December 2023), Novo Holdings-Catalent 16.5B (February 2024), Roche-Zealand petrelinitide 1.65B (2024), Pfizer-Metsera up to 10B headline (November 2025), and Novo-Akero 5.2B (late 2025). On access, semaglutide was selected for IRA Medicare drug price negotiation in 2025 with the negotiated maximum fair price effective January 2027, while the CMS Medicare GLP-1 Bridge program runs $50 per month copay July 2026 through December 2027 for eligible beneficiaries with covered cardiovascular indications. On pipeline, Lilly orforglipron (first oral non-peptide GLP-1) faces an expected Q2 2026 FDA decision, retatrutide (triple agonist) is in Phase 3, CagriSema was filed December 2025, and Amgen MariTide (monthly antibody-peptide conjugate) reads out Phase 3 late 2026. The franchise economics are durable but the dispersion across competitors is widening.

The investible universe sorts into six archetypes, each with different economics.

1. Incumbents (LLY, NVO). Lilly Mounjaro and Zepbound plus Novo Ozempic, Wegovy, and Rybelsus captured the vast majority of 2025 class revenue. Q1 2026 saw Lilly post 56 percent company revenue growth (Mounjaro +125 percent, Zepbound +80 percent) and Novo obesity care grow 22 percent at constant currency. Wegovy holds about 65 percent of US new prescriptions but Lilly overtook Novo in share outside the US in early 2026. Two-horse race today, with oral (orforglipron) and amylin combination (CagriSema) pipelines differentiating into 2026 to 2027.

2. Late-stage challengers (PFE, AMGN, RHHBY, AZN). Each entering through M&A or licensing. Pfizer absorbed Metsera November 2025 (about 7.3 billion upfront plus up to 3.5 billion contingent, about 10 billion headline) for an oral and injectable pipeline after danuglipron failed. Amgen MariTide (antibody-peptide conjugate with monthly dosing) Phase 3 readout expected late 2026. Roche CT-388 (Carmot, 23 percent placebo-adjusted at 48 weeks) entering Phase 3 in 2026, plus petrelinitide via Zealand. AstraZeneca AZD6234 (amylin) and ECC5004 (oral GLP-1). Different unit economics from incumbents: late timing forces M&A premiums and execution risk.

3. Mid- and small-cap pure-plays (VKTX, GPCR, ALT, ZEAL.CO). High-upside, binary readouts. Viking VK2735 dual GLP-1/GIP oral hit Phase 2 (10.9 percent placebo-adjusted at 13 weeks). Structure aleniglipron (Roche partnership). Altimmune pemvidutide MASH-first (IMPACT pivotal 2026). Zealand petrelinitide plus survodutide (Phase 3 with Boehringer Ingelheim). M&A-prone given big-pharma demand for assets.

4. Supply chain and CDMO enablers (BANB.SW, PPGN.SW, LONN.SW, TMO, YPSN.SW). Margin profile differs from branded pharma but earnings are less binary than late-stage biotech. CordenPharma EUR 1 billion plus peptide expansion through 2028; Bachem CHF approximately 400M expansion; Ypsomed primary autoinjector supplier to Novo. Capacity bottleneck of 2023 to 2024 eases through 2026 to 2028, which compresses the scarcity premium but supports volume growth.

5. Distribution and adjacency (HIMS, MDGL, AKRO, DXCM, ABT). Hims and Hers struck a Novo branded-distribution deal March 2026 and is unwinding its compounding subsidiary under FDA pressure. Madrigal Rezdiffra Q1 2026 net sales 311 million (+127 percent YoY) competes with GLP-1 in MASH. Akero acquired by Novo for 5.2 billion (FGF21 efruxifermin). Dexcom Stelo and Abbott Lingo OTC continuous glucose monitors are reframed for GLP-1 co-prescribing. Adjacency rather than core, but coupled to GLP-1 patient base growth.

6. International leaders and biosimilar (Innovent 1801.HK, Biocon, Sun Pharma, Dr. Reddy's). Innovent mazdutide approved by China NMPA June 2025 (first dual GCG/GLP-1 globally), partnered with Lilly. Biocon biosimilar semaglutide filed in Canada, Brazil, and West Asia at about 40 percent discount to Ozempic. EM biosimilar runway opens as the Chinese semaglutide patent expires early 2026.

Cross-cutting framing. Incumbents carry execution-de-risked compounding earnings but face IRA-negotiated price compression (semaglutide effective January 2027) and downstream biosimilar cliffs. Challengers carry development risk plus M&A optionality. Pure-plays carry binary readout risk with concentrated upside if assets reach licensing or acquisition. Supply chain CDMO and device makers carry lower binary risk but lower upside. The right comparison is rarely 'LLY versus NVO' in absolute terms. It is 'who captures what share of which patient pool given the access regime, the pipeline differentiation, and the IP runway.'